A mosquito-borne viral infection spreading in the Americas and Europe, caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. As of September 2020, there have been more than 3 million reported cases in the Americas1 and the economic impact is significant (e.g. Colombia outbreak 2014: $73.6m2).

About VLA1553

  • VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.
  • VLA1553 was granted Fast Track designation by the FDA in December 20183.
  • Valneva reported excellent final Phase 1 results for VLA1553 in November 20194.
  • Valneva successfully completed an End-of-Phase 2 meeting with the FDA and agreed on the clinical development plan towards licensure5.
  • Valneva initiated a pivotal Phase 3 trial for VLA1553 in September 20206.
  • The total duration of the study is expected to be nine months and the outcome, if positive, shall provide the basis for licensure of the vaccine.

 

Additional information about chikungunya: